title: Shaping of an effective immune microenvironment to and by cancer cells.
abstract: A high density of intratumoral effector memory CD8+/Th1 T cells is associated with favorable prognosis in most cancers and may be induced or increased by immunotherapy. Efficient adaptive immune reactions are shaped in tumor adjacent tertiary lymphoid structures, which exhibit all characteristics of immunity generating lymphoid formations in reactive lymph nodes. Malignant tumor cells impact favorably or deleteriously their immune microenvironment if they bear genetic mutations that result in neo-antigens or by producing chemokines and cytokines that recruit lymphocytes and myeloid cells or increase inflammation and neo-angiogenesis. This intricate network of interactions results in control or escape of tumors, and its understanding will help define goals to monitor efficiency of immunotherapies.
authors.affiliation: Laboratory Cancer, Immune Control and Escape, UMRS 1138 INSERM, Cordeliers Research Center, 15, rue de l'école de Médecine, 75270, Paris Cedex 06, France.
authors.forename: Etienne
authors.initials: E
authors.lastname: Becht
authors.forename: Jeremy
authors.initials: J
authors.lastname: Goc
authors.forename: Claire
authors.initials: C
authors.lastname: Germain
authors.forename: Nicolas A
authors.initials: NA
authors.lastname: Giraldo
authors.forename: Marie-Caroline
authors.initials: MC
authors.lastname: Dieu-Nosjean
authors.forename: Catherine
authors.initials: C
authors.lastname: Sautès-Fridman
authors.forename: Wolf-Herman
authors.initials: WH
authors.lastname: Fridman
mesh_terms: D000818:Animals; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D011379:Prognosis; D059016:Tumor Microenvironment / Q000276:immunology*
references.citation: Cancer Res. 2011 Oct 15;71(20):6391-9
references.pmid: 21900403
references.citation: Curr Opin Immunol. 2014 Apr;27:8-15
references.pmid: 24487185
references.citation: Curr Opin Immunol. 2014 Apr;27:16-25
references.pmid: 24531241
references.citation: Nat Rev Immunol. 2011 Sep 23;11(10):702-11
references.pmid: 21941296
references.citation: J Clin Oncol. 2013 Feb 20;31(6):692-700
references.pmid: 23182984
references.citation: Sci Transl Med. 2014 Mar 19;6(228):228ra37
references.pmid: 24648340
references.citation: Immunity. 2013 Oct 17;39(4):782-95
references.pmid: 24138885
references.citation: J Clin Oncol. 2009 Dec 10;27(35):5944-51
references.pmid: 19858404
references.citation: Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
references.pmid: 24484236
references.citation: N Engl J Med. 2013 Apr 18;368(16):1509-1518
references.pmid: 23527958
references.citation: Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10662-7
references.pmid: 21670304
references.citation: J Clin Oncol. 2008 Sep 20;26(27):4410-7
references.pmid: 18802153
references.citation: Immunol Rev. 2010 Jan;233(1):267-85
references.pmid: 20193005
references.citation: PLoS Med. 2013;10(5):e1001453
references.pmid: 23700391
references.citation: N Engl J Med. 2012 Jun 28;366(26):2455-65
references.pmid: 22658128
references.citation: Nature. 2012 Feb 08;482(7385):400-4
references.pmid: 22318521
references.citation: Science. 2006 Sep 29;313(5795):1960-4
references.pmid: 17008531
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Cancer Res. 2014 Feb 1;74(3):705-15
references.pmid: 24366885
references.citation: Clin Cancer Res. 2013 Aug 1;19(15):4079-91
references.pmid: 23785047
references.citation: Trends Immunol. 2014 Nov;35(11):571-80
references.pmid: 25443495
references.citation: Science. 2013 Mar 29;339(6127):1546-58
references.pmid: 23539594
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: Immunity. 2006 Oct;25(4):643-54
references.pmid: 17045819
references.citation: J Transl Med. 2012 Oct 03;10:205
references.pmid: 23034130
references.citation: Sci Transl Med. 2014 Jan 29;6(221):221ra13
references.pmid: 24477000
references.citation: Clin Dev Immunol. 2012;2012:492920
references.pmid: 23320019
references.citation: Cancer Immunol Immunother. 2011 Dec;60(12):1729-38
references.pmid: 21779876
references.citation: J Clin Invest. 2013 Jul;123(7):2873-92
references.pmid: 23778140
references.citation: J Clin Oncol. 2011 Feb 20;29(6):610-8
references.pmid: 21245428
references.citation: Breast Cancer Res Treat. 2012 Apr;132(2):545-53
references.pmid: 21671016
references.citation: N Engl J Med. 2005 Dec 22;353(25):2654-66
references.pmid: 16371631
references.citation: Clin Cancer Res. 2015 Mar 15;21(6):1329-39
references.pmid: 25583177
references.citation: J Immunol. 2010 Jul 1;185(1):717-28
references.pmid: 20525884
references.citation: Curr Opin Infect Dis. 2006 Feb;19(1):14-9
references.pmid: 16374212
references.citation: Nat Rev Cancer. 2012 Mar 15;12(4):298-306
references.pmid: 22419253
references.citation: Nature. 2011 Dec 21;480(7378):480-9
references.pmid: 22193102
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: Cancer Res. 2001 Jul 1;61(13):5132-6
references.pmid: 11431351
references.citation: Invest Ophthalmol Vis Sci. 1993 Jul;34(8):2603-6
references.pmid: 8325762
references.citation: Trends Immunol. 2012 Jun;33(6):297-305
references.pmid: 22622061
references.citation: Oncoimmunology. 2012 Sep 1;1(6):829-839
references.pmid: 23162750
references.citation: Cancer Res. 2011 Sep 1;71(17):5678-87
references.pmid: 21846823
references.citation: J Exp Med. 2000 Sep 4;192(5):705-18
references.pmid: 10974036
references.citation: Int J Cancer. 1995 Jan 17;60(2):183-9
references.pmid: 7829213